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Aim: Osteocalcin and undercarboxylated osteocalcin are suggested to be endocrine
messengers from the bones and have been shown to stimulate insulin secretion from
pancreatic β-cells. Insulin is hypothesized to increase the osteoblastic production of
osteocalcin. The aim of the study was to investigate whether the route of glucose
administration influence the circulating levels of osteocalcin and undercarboxylated
osteocalcin.
Methods : Twelve healthy males were enrolled in an acute cross-over study where they
underwent an oral glucose tolerance test (OGTT), an isoglycemic intravenous glucose
infusion (IIGI) and a fasting period (control). Blood samples were collected throughout
180min and analyzed for osteocalcin and undercarboxylated osteocalcin and compared
to insulin, glucose, and gastro-intestinal hormone responses.
Results: Neither osteocalcin levels nor undercarboxylated osteocalcin levels over
time differed between the OGTT, IIGI, and fasting. Baseline insulin levels and glucose
levels were not associated with osteocalcin or undercarboxylated osteocalcin levels.
Increases in insulin and glucose levels were neither associated with altered osteocalcin
nor undercarboxylated osteocalcin levels.
Conclusion: The route of glucose administration does not influence the circulating
levels of osteocalcin and undercarboxylated osteocalcin despite the differential insulin
and incretin responses. In the acute setting this suggests that insulin does not increase
osteoblastic production of osteocalcin in healthy human males.
Keywords: osteocalcin, undercarboxylated osteocalcin, glucose, insulin, oral glucose tolerance test, isoglycemic
intravenous glucose infusion
INTRODUCTION
Osteocalcin is suggested to be an endocrine product and messengers from the bones. Osteocalcin is
produced by the osteoblasts and becomes undercarboxylated through the acidification in relation
to bone resorption (1). In animal models undercarboxylated osteocalcin is proposed to increase
insulin production and release by a direct effect on pancreatic β-cells (1–3). Conversely, insulin is
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believed to affect the osteoblasts directly and to increase
osteocalcin production (1). Thus, a positive feedback-cycle
where osteocalcin and undercarboxylated osteocalcin modulate
glucose metabolism has been proposed to exist (1). In
humans osteocalcin and undercarboxylated osteocalcin are
inversely associated with fasting plasma glucose and glycated
hemoglobin A1c supporting the hypothesis of a bone pancreas-
axis (4). Furthermore, postmenopausal osteoporotic females
treated with parathyroid hormone (PTH) have increased
circulating osteocalcin and undercarboxylated osteocalcin levels
and decrease blood glucose levels during an oral glucose
tolerance test (5). However, in hypoparathyroid individuals
treated with PTH an increase in undercarboxylated osteocalcin
does not affect fasting plasma glucose or insulin resistance
(6).
An oral glucose tolerance test (OGTT) and an intravenous
isoglycemic glucose infusion (IIGI) results in differential insulin
and incretin hormone responses despite comparable levels of
plasma glucose (7, 8). The aim of the present study is to
investigate whether administration of glucose by two different
routes resulting in differential incretin and insulin responses
differentially influences osteocalcin and undercarboxylated
osteocalcin levels.
PATIENTS AND METHODS
The study was registered at ClinicalTrials.gov (NCT02213276).
Approval was obtained from the Danish Data Protection
Agency (2007-58-0010) and the Ethics Committee of the Central
Denmark Region (1-16-02-377-13) and relevant guidelines
were followed. All subjects gave written informed consent in
accordance with the Declaration of Helsinki. The STROBE
guidelines were followed (Supplemental Table 1). The study
design has been described previously in detail (8). In the study
we included relatively young individuals and to avoid potential
effects of fluctuations in sex hormones on bone markers during
the menstrual cycle we only enrolled males. Briefly, 12 healthy
Caucasian males, aged 20 to 50 years, were included in the
study and underwent an OGTT and an IIGI. Eight of the
participants also engaged in a fasting control. During the OGTT
participants drank a glucose solution consisting of 82.5 g of
glucose monohydrate (equal to 75 g of D-glucose), 225ml of
water and 225mg of benzoic acid over 5min. For the IIGI 20%
D-glucose was infused in the antecubital vein and mimicked
the glucose levels of the OGTT by adjusting the infusion rate
for the glucose solution according to the plasma glucose level.
Blood samples were collected at −15, −10, 0, 15, 30, 60, 120,
and 180min from initiation of the glucose administration at the
OGTT and IIGI and plasma glucose levels were measured every
5min. A fasting control study (without glucose administration)
was also performed where blood samples were collected after
0, 1, 2, and 3 h. The day before each intervention, participants
were asked to refrain from exercise, smoking and taking vitamin
supplements. A standard meal delivered by the clinic was to be
ingested between 17 and 23 o’clock and participants were asked
to fast (water allowed) from 23 o’clock until they arrived for the
intervention the next morning. They were asked to arrive by car
or bus to the clinic.
Biochemical Measures
Manufacturer determined standard deviations for intermediate
precision is 0.1µM, within a glucose concentration of 2.5–
6.5µM. Serum levels of osteocalcin were measured on an
automated Cobas E601 analyzer (Roche Diagnostics, Mannheim,
Germany) and quality control material parallelly measured with
test samples resulted in variation coefficients less than 1%. EDTA-
plasma levels of undercarboxylated osteocalcin were measured
by ELISA (Takara Bio Inc, Otsu, Japan) and samples from each
participant were analyzed within a single ELISA-plate. Within
plate precision judged from duplicate measurements attained
variation coefficients less than 4%. Intermediate precision
determined by analyzing quality control material resulted in
variation coefficients less than 10%.
Analysis of and data on plasma glucose, plasma insulin,
glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-
2), and gastric inhibitory peptide (GIP) have previously been
described (8).
Briefly, plasma glucose was measured using the Accu-Chek
Inform II apparatus (Roche Diagnostics, Basel, Switzerland) and
plasma insulin was measured by ELISA using a DAKO insulin kit
(Code: K6219; Dako, Glostrup, Denmark).
Statistical Analysis
Statistical analysis was carried out using the STATA 14
package (StataCorp, College Station, Texas, USA). Repeated
measures ANOVA was performed to compare levels of
osteocalcin, undercarboxylated osteocalcin, insulin, glucose, and
gastrointestinal hormones between OGTT, IIGI and the 3-h
fasting control. Normality of data was checked via qq-plots. The
compound symmetry assumption was checked by examining
the pooled within-subject covariance. We performed three
conservative F-tests to ensure validity of results.
Using a simple linear regression model, the association
between the increase in insulin, GIP, GLP-1, GLP-2, and
glucose from 0 to 30min and alterations in osteocalcin
and undercarboxylated osteocalcin during same time period
were examined. Furthermore, the association between baseline
osteocalcin, undercarboxylated osteocalcin and insulin and
glucose were analyzed by simple linear regression. No power
calculation was performed on osteocalcin or undercarboxylated
osteocalcin Osteocalcin measurement was a secondary outcome
measured subsequent to the publication of the main findings.
This was performed in order to gain further knowledge. The
primary endpoint of the study was CTX which is previously
published (8).
RESULTS
The mean age of the healthy participants was 30.6 years and
the mean body mass index was 24.2 kg/m2. All participants
presented with normal HbA1c. The participant characteristics
have previously been described. Figure 1 presents the responses
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FIGURE 1 | Plasma osteocalcin, undercarboxylated osteocalcin, insulin, and glucose responses to oral glucose tolerance test (OGTT), intravenous isoglycemic
glucose infusion (IIGI) and fasting by time. *Significantly different between OGTT, IIGI and fasting (P < 0.05). # No difference was detected between OGTT, IIGI, and
fasting (P > 0.05). The error bars represent 95% confidence intervals. Undercarboxylated osteocalcin (UcOc).
of osteocalcin, undercarboxylated osteocalcin, insulin, and
glucose by time and intervention.
As intended, the plasma glucose curves levels were
comparable during the OGTT and IIGI. The insulin
concentrations increased during the OGTT and IIGI with
peak values at 30min (274 vs. 32 pM and 111 vs. 34 pM,
respectively). No changes in insulin or glucose concentrations
were observed during fasting.
Baseline levels of osteocalcin were 32.2 ± 9.3, 33.4 ± 8.5, and
31.7 ± 8.3 ng/ml at the OGTT, IIGI, and fasting interventions,
respectively. Baseline levels of undercarboxylated osteocalcin
were 7.3 ± 3.2, 7.5 ± 2.8, and 6.5 ± 2.3 ng/ml at the OGTT,
IIGI, and fasting interventions, respectively. No interaction was
observed between time and type of intervention for osteocalcin
and undercarboxylated osteocalcin (P > 0.05). Osteocalcin
and undercarboxylated osteocalcin levels were not significantly
different at any time points between OGTT, IIGI, and fasting
(P > 0.05).
During the OGTT osteocalcin decreased significantly at
60min (30.0 ± 8.4 ng/ml), 120min (29.4 ± 8.1 ng/ml), and
180min (29.6 ± 8.2 ng/ml) compared to baseline. During the
IIGI osteocalcin decreased significantly at 120min (30.9 ±
7.2 ng/ml) and 180min (30.4 ± 7.3 ng/ml) compared to baseline
whereas fasting only decreased osteocalcin at 180min (29 ±
7.2 ng/ml) compared to baseline.
Undercarboxylated osteocalcin decreased significantly at
180min (6.7 ± 2.8 ng/ml) during the OGTT and at 60min
(6.9 ± 2.6 ng/ml) and 180min (6.9 ± 2.6 ng/ml) during the
IIGI compared to baseline. No difference in undercarboxylated
osteocalcin was observed over time during fasting.
Simple linear regression showed no association between
baseline osteocalcin or undercarboxylated osteocalcin and
glucose or insulin (P > 0.05). Furthermore, no association was
observed between alterations in osteocalcin or undercarboxylated
osteocalcin and increases in insulin, glucose, GIP, GLP-1, and
GLP-2 from baseline to 30min (P > 0.05).
DISCUSSION
In the present study we observed no increase in osteocalcin
or undercarboxylated osteocalcin in response to glucose
administration either orally or intravenously although these tests
resulted in widely different insulin responses. Both during the
OGTT and IIGI osteocalcin seemed to decrease over time. The
results do not support the hypothesis of an increased osteocalcin
production due to osteoblastic activation by insulin, at least in the
acute setting in metabolically healthy people.
Our results corroborate previous human data. Insulin infused
at high, intermediate and low doses neither affected the level
of undercarboxylated osteocalcin in participants with type 2
diabetes nor in healthy individuals (9). Furthermore, OGTT
has previously been shown to decrease osteocalcin as well as
undercarboxylated osteocalcin (10, 11) and osteocalcin levels
decreased during a hyperinsulinemic, euglycemic clamp in obese
people (12). Antiresorptive therapies are hypothesized to increase
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undercarboxylated osteocalcin and thereby decrease diabetes
incidence, however, in a post-hoc analysis of three randomized
controlled trials the antiresorptive therapy did not affect fasting
plasma glucose, weight loss, or diabetes risk (13).
Current human data do not support a causal relationship
between increased insulin levels leading to increased osteocalcin
and undercarboxylated osteocalcin levels. However, delta-like 1
(DLK1) that is co-localized with insulin in the pancreatic β-cells
may affect these bone formation markers. DLK1 deficient mice
expressed high levels of osteocalcin, whereas mice overexpressing
DLK1 had low levels of osteocalcin (14). DLK1 may therefore
counteract the positive feedback loop between osteocalcin and
endogenous insulin (14).
The reduction in osteocalcin observed during the OGTT was
comparable to that observed during the fasting. Thus there was
a time-related decline during the interventions. During OGTT,
both bone resorption markers and bone formation markers
decrease in 20min, however, this effect is abolished by the
somatostatin analog octreotide, which inhibits the release of
gastrointestinal hormones (15). In the present study osteocalcin
and undercarboxylated osteocalcin were not related to circulating
levels of gastro-intestinal hormones. The discrepancy compared
with previous studies may be due to differences in subject
characteristics.
In people with diabetes, osteocalcin levels are lower than in
non-diabetic controls and the osteocalcin levels are negatively
associated with glucose (16, 17). This may explain the association
found in the meta-analysis by Liu et al. (4). It is likely to find
an inverse association between osteocalcin and fasting plasma
glucose in people with and without diabetes. Thus, fasting people
with diabetes have lower levels of osteocalcin, higher levels of
glucose and lower levels of insulin.
This study was a controlled experiment. However, it was not
possible to blind the participants. Furthermore, the results may
be different in metabolic dysregulated individuals and in women.
The sample size of the study is limited and the follow-up time is
relatively short which may have influenced the results.
In conclusion, we observed no differences in osteocalcin or
undercarboxylated osteocalcin responses glucose challenges
resulting in widely different endogenous insulin and
incretin responses. Our results suggest that insulin does
not increase osteoblastic production of osteocalcin in healthy
humans.
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